Jeffrey Lieberman, M.D. - Publications

Affiliations: 
Psychiatry Columbia University, New York, NY 

311 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Lieberman JA, Michels R. A Scientific Pioneer of Psychiatry. The American Journal of Psychiatry. 173: 574. PMID 27245190 DOI: 10.1176/appi.ajp.2015.15091167  0.72
2016 Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, Cho RY, Carter CS, Slifstein M, Abi-Dargham A, Lieberman JA. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. Journal of Psychopharmacology (Oxford, England). PMID 26966119 DOI: 10.1177/0269881116636120  0.72
2016 Taylor DL, Tiwari AK, Lieberman JA, Potkin SG, Meltzer HY, Knight J, Remington G, Müller DJ, Kennedy JL. Genetic association analysis of N-methyl-d-aspartate receptor subunit gene GRIN2B and clinical response to clozapine. Human Psychopharmacology. PMID 26876050 DOI: 10.1002/hup.2519  0.72
2016 Huang E, Zai CC, Lisoway A, Maciukiewicz M, Felsky D, Tiwari AK, Bishop JR, Ikeda M, Molero P, Ortuno F, Porcelli S, Samochowiec J, Mierzejewski P, Gao S, Crespo-Facorro B, ... ... Lieberman JA, et al. Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). PMID 26745992 DOI: 10.1093/ijnp/pyv132  0.72
2015 Tiwari AK, Brandl EJ, Zai CC, Goncalves VF, Chowdhury NI, Freeman N, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 1-9. PMID 26447462 DOI: 10.3109/15622975.2015.1076173  0.72
2015 Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tamminga CA, Mates S, Vanover KE. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. Biological Psychiatry. PMID 26444072 DOI: 10.1016/j.biopsych.2015.08.026  0.72
2015 Lieberman JA. Response to Kornfeld. The American Journal of Psychiatry. 172: 911. PMID 26324309 DOI: 10.1176/appi.ajp.2015.15070863r  0.72
2015 Brandl EJ, Tiwari AK, Zai CC, Nurmi EL, Chowdhury NI, Arenovich T, Sanches M, Goncalves VF, Shen JJ, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample. The Pharmacogenomics Journal. PMID 26323598 DOI: 10.1038/tpj.2015.59  0.72
2015 Lee SH, Byrne EM, Hultman CM, Kähler A, Vinkhuyzen AA, Ripke S, Andreassen OA, Frisell T, Gusev A, Hu X, Karlsson R, Mantzioris VX, McGrath JJ, Mehta D, Stahl EA, ... ... Lieberman JA, et al. New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. International Journal of Epidemiology. PMID 26286434 DOI: 10.1093/ije/dyv136  0.72
2015 Girgis RR, Xu X, Gil RB, Hackett E, Ojeil N, Lieberman JA, Slifstein M, Abi-Dargham A. Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [(11)C]-(+)-PHNO. Schizophrenia Research. 168: 373-6. PMID 26190300 DOI: 10.1016/j.schres.2015.06.027  0.72
2015 Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, ... Lieberman JA, et al. A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia Research. 164: 136-42. PMID 25728831 DOI: 10.1016/j.schres.2015.01.041  0.72
2015 Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D'Souza D, Malison RT, Huang Y, Lim K, Nabulsi N, ... ... Lieberman JA, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. Jama Psychiatry. 72: 316-24. PMID 25651194 DOI: 10.1001/jamapsychiatry.2014.2414  0.72
2015 Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, Harvey PD, Girgis RR, Hazlett EA, Mailman RB, Abi-Dargham A, Lieberman JA, Siever LJ. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 446-53. PMID 25074637 DOI: 10.1038/npp.2014.192  0.72
2014 Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials: a meta-analysis. Jama Psychiatry. 71: 1409-21. PMID 25321611 DOI: 10.1001/jamapsychiatry.2014.1319  0.72
2014 Bargmann CI, Lieberman JA. What the BRAIN Initiative means for psychiatry. The American Journal of Psychiatry. 171: 1038-40. PMID 25272342 DOI: 10.1176/appi.ajp.2014.14081029  0.72
2014 Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends in Endocrinology and Metabolism: Tem. 25: 593-600. PMID 25190097 DOI: 10.1016/j.tem.2014.07.004  0.72
2014 Goldstein JI, Jarskog LF, Hilliard C, Alfirevic A, Duncan L, Fourches D, Huang H, Lek M, Neale BM, Ripke S, Shianna K, Szatkiewicz JP, Tropsha A, van den Oord EJ, Cascorbi I, ... ... Lieberman JA, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nature Communications. 5: 4757. PMID 25187353 DOI: 10.1038/ncomms5757  0.72
2014 Lieberman JA. Our future is now. The American Journal of Psychiatry. 171: 733-7. PMID 24980171 DOI: 10.1176/appi.ajp.2014.1710702  0.72
2014 Brandl EJ, Tiwari AK, Zai CC, Chowdhury NI, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain. Psychiatry Research. 219: 255-60. PMID 24953421 DOI: 10.1016/j.psychres.2014.05.031  0.72
2014 Li X, Liu J, Duan N, Jiang H, Girgis R, Lieberman J. Cumulative sojourn time in longitudinal studies: a sequential imputation method to handle missing health state data due to dropout. Statistics in Medicine. 33: 2030-47. PMID 24918241 DOI: 10.1002/sim.6090  0.72
2014 DuPont RL, Lieberman JA. Young brains on drugs. Science (New York, N.Y.). 344: 557. PMID 24812368 DOI: 10.1126/science.1254989  0.72
2014 Gagliano SA, Tiwari AK, Freeman N, Lieberman JA, Meltzer HY, Kennedy JL, Knight J, Müller DJ. Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain. Human Psychopharmacology. 29: 330-5. PMID 24737441 DOI: 10.1002/hup.2407  0.72
2014 Kao AC, Rojnic Kuzman M, Tiwari AK, Zivkovic MV, Chowdhury NI, Medved V, Kekin I, Zai CC, Lieberman JA, Meltzer HY, Bozina T, Bozina N, Kennedy JL, Sertic J, Müller DJ. Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. Journal of Psychiatric Research. 54: 36-42. PMID 24725652 DOI: 10.1016/j.jpsychires.2014.03.012  0.72
2014 Brandl EJ, Tiwari AK, Chowdhury NI, Zai CC, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. Pharmacogenomics. 15: 423-31. PMID 24624910 DOI: 10.2217/pgs.13.247  0.72
2014 Graham KA, Keefe RS, Lieberman JA, Calikoglu AS, Lansing KM, Perkins DO. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Intervention in Psychiatry. PMID 24612563 DOI: 10.1111/eip.12122  0.48
2014 Chowdhury NI, Souza RP, Tiwari AK, Brandl EJ, Sicard M, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ. Investigation of melanocortin system gene variants in antipsychotic-induced weight gain. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 15: 251-8. PMID 24564533 DOI: 10.3109/15622975.2013.858827  0.72
2014 Shing EC, Tiwari AK, Brandl EJ, Zai CC, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Fat mass- and obesity-associated (FTO) gene and antipsychotic-induced weight gain: an association study. Neuropsychobiology. 69: 59-63. PMID 24481458 DOI: 10.1159/000356231  0.72
2014 Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophrenia Research. 152: 325-32. PMID 24418122 DOI: 10.1016/j.schres.2013.12.013  0.72
2014 Gonçalves VF, Zai CC, Tiwari AK, Brandl EJ, Derkach A, Meltzer HY, Lieberman JA, Müller DJ, Sun L, Kennedy JL. A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 1347-54. PMID 24196945 DOI: 10.1038/npp.2013.312  0.72
2014 Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Molecular Psychiatry. 19: 20-9. PMID 24166406 DOI: 10.1038/mp.2013.136  0.72
2014 Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA. A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia Nature. 508: 968-975.  0.72
2013 Lieberman JA. Response to the presidential address. The American Journal of Psychiatry. 170: 1106-7. PMID 24084816 DOI: 10.1176/appi.ajp.2013.1701002  0.72
2013 Zai CC, Tiwari AK, Mazzoco M, de Luca V, Müller DJ, Shaikh SA, Lohoff FW, Freeman N, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. Journal of Psychiatric Research. 47: 1760-5. PMID 24018103 DOI: 10.1016/j.jpsychires.2013.07.025  0.72
2013 Lieberman JA, Dixon LB, Goldman HH. Early detection and intervention in schizophrenia: a new therapeutic model. Jama. 310: 689-90. PMID 23989167 DOI: 10.1001/jama.2013.8804  0.72
2013 Chan LF, Zai C, Monda M, Potkin S, Kennedy JL, Remington G, Lieberman J, Meltzer HY, De Luca V. Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics. 14: 1273-81. PMID 23930674 DOI: 10.2217/pgs.13.127  0.72
2013 Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, Golden LH, Lieberman JA, Stroup TS. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. The American Journal of Psychiatry. 170: 1032-40. PMID 23846733 DOI: 10.1176/appi.ajp.2013.12010127  0.72
2013 Fisher CE, Lieberman JA. Getting the facts straight about gun violence and mental illness: putting compassion before fear. Annals of Internal Medicine. 159: 423-4. PMID 23836046 DOI: 10.7326/0003-4819-159-5-201309030-00679  0.72
2013 Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, Inbar BP, Corcoran CM, Lieberman JA, Moore H, Small SA. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 78: 81-93. PMID 23583108 DOI: 10.1016/j.neuron.2013.02.011  0.72
2013 Lett TA, Chakravarty MM, Chakavarty MM, Felsky D, Brandl EJ, Tiwari AK, Gonçalves VF, Rajji TK, Daskalakis ZJ, Meltzer HY, Lieberman JA, Lerch JP, Mulsant BH, Kennedy JL, Voineskos AN. The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Molecular Psychiatry. 18: 443-50. PMID 23459466 DOI: 10.1038/mp.2013.17  0.72
2013 Colibazzi T, Wexler BE, Bansal R, Hao X, Liu J, Sanchez-Peña J, Corcoran C, Lieberman JA, Peterson BS. Anatomical abnormalities in gray and white matter of the cortical surface in persons with schizophrenia. Plos One. 8: e55783. PMID 23418459 DOI: 10.1371/journal.pone.0055783  0.72
2013 Brandl EJ, Tiwari AK, Lett TA, Shaikh SA, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. Human Psychopharmacology. 28: 183-7. PMID 23364847 DOI: 10.1002/hup.2288  0.72
2013 Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, ... ... Lieberman JA, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 1245-52. PMID 23325325 DOI: 10.1038/npp.2013.23  0.72
2013 Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA. A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 968-75. PMID 23303043 DOI: 10.1038/npp.2012.259  0.72
2013 Tiwari AK, Brandl EJ, Weber C, Likhodi O, Zai CC, Hahn MK, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. Journal of Clinical Psychopharmacology. 33: 11-7. PMID 23277265 DOI: 10.1097/JCP.0b013e31827d145a  0.72
2013 Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 14: 2-44. PMID 23216388 DOI: 10.3109/15622975.2012.739708  0.72
2013 McClure RK, Styner M, Maltbie E, Lieberman JA, Gouttard S, Gerig G, Shi X, Zhu H. Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type. Psychiatry Research. 211: 1-10. PMID 23142194 DOI: 10.1016/j.pscychresns.2012.07.001  0.72
2013 Huey ED, Nagy PL, Rodriguez-Murillo L, Manoochehri M, Goldman J, Lieberman J, Karayiorgou M, Mayeux R. C9ORF72 repeat expansions not detected in a group of patients with schizophrenia. Neurobiology of Aging. 34: 1309.e9-10. PMID 23036583 DOI: 10.1016/j.neurobiolaging.2012.08.011  0.72
2013 Nowrouzi B, Souza RP, Zai C, Shinkai T, Monda M, Lieberman J, Volvaka J, Meltzer HY, Kennedy JL, De Luca V. Finite mixture regression model analysis on antipsychotics induced weight gain: investigation of the role of the serotonergic genes. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 224-8. PMID 22840963 DOI: 10.1016/j.euroneuro.2012.05.008  0.72
2013 Crowley JJ, Hilliard CE, Kim Y, Morgan MB, Lewis LR, Muzny DM, Hawes AC, Sabo A, Wheeler DA, Lieberman JA, Sullivan PF, Gibbs RA. Deep resequencing and association analysis of schizophrenia candidate genes. Molecular Psychiatry. 18: 138-40. PMID 22472875 DOI: 10.1038/mp.2012.28  0.72
2013 Chowdhury NI, Tiwari AK, Souza RP, Zai CC, Shaikh SA, Chen S, Liu F, Lieberman JA, Meltzer HY, Malhotra AK, Kennedy JL, Müller DJ. Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. The Pharmacogenomics Journal. 13: 272-9. PMID 22310352 DOI: 10.1038/tpj.2011.66  0.72
2012 Mamah D, Harms MP, Barch D, Styner M, Lieberman JA, Wang L. Hippocampal shape and volume changes with antipsychotics in early stage psychotic illness. Frontiers in Psychiatry. 3: 96. PMID 23162479 DOI: 10.3389/fpsyt.2012.00096  0.72
2012 Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 13: 318-78. PMID 22834451 DOI: 10.3109/15622975.2012.696143  0.72
2012 Sherer EA, Sale ME, Pollock BG, Belani CP, Egorin MJ, Ivy PS, Lieberman JA, Manuck SB, Marder SR, Muldoon MF, Scher HI, Solit DB, Bies RR. Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. Journal of Pharmacokinetics and Pharmacodynamics. 39: 393-414. PMID 22767341 DOI: 10.1007/s10928-012-9258-0  0.72
2012 Hirata Y, Zai CC, Souza RP, Lieberman JA, Meltzer HY, Kennedy JL. Association study of GRIK1 gene polymorphisms in schizophrenia: case-control and family-based studies. Human Psychopharmacology. 27: 345-51. PMID 22730074 DOI: 10.1002/hup.2233  0.72
2012 Zai GC, Zai CC, Chowdhury NI, Tiwari AK, Souza RP, Lieberman JA, Meltzer HY, Potkin SG, Müller DJ, Kennedy JL. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 39: 96-101. PMID 22642961 DOI: 10.1016/j.pnpbp.2012.05.014  0.72
2012 Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry. 17: 1206-27. PMID 22584864 DOI: 10.1038/mp.2012.47  0.72
2012 Frazier JA, Giuliano AJ, Johnson JL, Yakutis L, Youngstrom EA, Breiger D, Sikich L, Findling RL, McClellan J, Hamer RM, Vitiello B, Lieberman JA, Hooper SR. Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. Journal of the American Academy of Child and Adolescent Psychiatry. 51: 496-505. PMID 22525956 DOI: 10.1016/j.jaac.2012.02.001  0.72
2012 Brandl EJ, Frydrychowicz C, Tiwari AK, Lett TA, Kitzrow W, Büttner S, Ehrlich S, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ, Puls I. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 38: 134-41. PMID 22426215 DOI: 10.1016/j.pnpbp.2012.03.001  0.72
2012 Souza RP, Tiwari AK, Chowdhury NI, Ceddia RB, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. Journal of Psychiatric Research. 46: 462-8. PMID 22305490 DOI: 10.1016/j.jpsychires.2012.01.010  0.72
2012 Hwang R, Tiwari AK, Zai CC, Felsky D, Remington E, Wallace T, Tong RP, Souza RP, Oh G, Potkin SG, Lieberman JA, Meltzer HY, Kennedy JL. Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 37: 62-75. PMID 22203087 DOI: 10.1016/j.pnpbp.2011.11.018  0.72
2012 Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophrenia Research. 136: 25-31. PMID 22169248 DOI: 10.1016/j.schres.2011.11.001  0.72
2012 Olfson M, Gerhard T, Huang C, Lieberman JA, Bobo WV, Crystal S. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Schizophrenia Bulletin. 38: 845-53. PMID 21307041 DOI: 10.1093/schbul/sbq172  0.72
2012 Tiwari AK, Zai CC, Likhodi O, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Müller DJ, Kennedy JL. Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. The Pharmacogenomics Journal. 12: 260-6. PMID 21266946 DOI: 10.1038/tpj.2010.93  0.72
2012 Müller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK, Hwang R, Likhodi O, Shaikh S, Freeman N, Arenovich T, Heinz A, Meltzer HY, Lieberman JA, Kennedy JL. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. The Pharmacogenomics Journal. 12: 156-64. PMID 20714340 DOI: 10.1038/tpj.2010.65  0.72
2012 Huey ED, Lieberman JA. From known to unknown; Old to new: Can lesion studies inform psychiatry about mental illness in the 21st century? Neuropsychiatry. 2: 369-372. DOI: 10.2217/npy.12.54  0.72
2011 Roberts CE, Mortenson LY, Merrill DB, Rafizadeh N, Smith TE, Lieberman JA. Successful rechallenge with clozapine after eosinophilia. The American Journal of Psychiatry. 168: 1147-51. PMID 22193601 DOI: 10.1176/appi.ajp.2010.10040519  0.72
2011 Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, et al. Advancing drug discovery for schizophrenia. Annals of the New York Academy of Sciences. 1236: 30-43. PMID 22032400 DOI: 10.1111/j.1749-6632.2011.06216.x  0.72
2011 Lett TA, Tiwari AK, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN, Kennedy JL, Müller DJ. The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. Schizophrenia Research. 132: 121-4. PMID 21890328 DOI: 10.1016/j.schres.2011.08.007  0.72
2011 De Luca V, Souza RP, Viggiano E, Sickert L, Teo C, Zai C, Tiwari AK, Müller DJ, Lieberman JA, Volavka J, Meltzer HY, Kennedy JL. Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain. Human Psychopharmacology. 26: 386-91. PMID 21823169 DOI: 10.1002/hup.1219  0.72
2011 Lieberman JA, Stroup TS. The NIMH-CATIE Schizophrenia Study: what did we learn? The American Journal of Psychiatry. 168: 770-5. PMID 21813492 DOI: 10.1176/appi.ajp.2011.11010039  0.72
2011 Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). The American Journal of Psychiatry. 168: 947-56. PMID 21768610 DOI: 10.1176/appi.ajp.2011.10111609  0.72
2011 Shi X, Ibrahim JG, Lieberman J, Styner M, Zhu H. TWO-STAGE EMPIRICAL LIKELIHOOD FOR LONGITUDINAL NEUROIMAGING DATA. The Annals of Applied Statistics. 5: 1132-1158. PMID 21765885 DOI: 10.1214/11-AOAS480  0.72
2011 Marx CE, Bradford DW, Hamer RM, Naylor JC, Allen TB, Lieberman JA, Strauss JL, Kilts JD. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience. 191: 78-90. PMID 21756978 DOI: 10.1016/j.neuroscience.2011.06.076  0.72
2011 Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, Kim SY, Manschreck TC, Boshes RA, McEvoy JP, Lieberman JA. Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophrenia Research. 130: 47-52. PMID 21561740 DOI: 10.1016/j.schres.2011.04.012  0.72
2011 Yolken RH, Torrey EF, Lieberman JA, Yang S, Dickerson FB. Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophrenia Research. 128: 61-5. PMID 21353483 DOI: 10.1016/j.schres.2011.01.020  0.72
2011 Hwang R, Souza RP, Tiwari AK, Zai CC, Müller DJ, Potkin SG, Lieberman JA, Meltze HY, Kennedy JL. Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. Pharmacogenomics. 12: 277-91. PMID 21332319 DOI: 10.2217/pgs.10.182  0.72
2011 Souza RP, Meltzer HY, Lieberman JA, Voineskos AN, Remington G, Kennedy JL. Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective. Human Psychopharmacology. 26: 21-7. PMID 21305610 DOI: 10.1002/hup.1161  0.72
2011 Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, Li CH, Coley K, Kirshner MM, Marder SR. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. Journal of Clinical Pharmacology. 51: 1587-91. PMID 21209243 DOI: 10.1177/0091270010387604  0.72
2011 Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, Kane J, McEvoy J, Lieberman J. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Research. 187: 42-8. PMID 21168920 DOI: 10.1016/j.psychres.2010.11.017  0.72
2011 Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biological Psychiatry. 69: 442-9. PMID 21145041 DOI: 10.1016/j.biopsych.2010.09.052  0.72
2011 McClay JL, Adkins DE, Aberg K, Bukszár J, Khachane AN, Keefe RS, Perkins DO, McEvoy JP, Stroup TS, Vann RE, Beardsley PM, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 616-26. PMID 21107309 DOI: 10.1038/npp.2010.193  0.72
2011 Girgis RR, Merrill DB, Vorel SR, Edward Kim, Kimberly Portland, You M, Pikalov A, Whitehead R, Lieberman JA. Aripiprazole versus haloperidol treatment in early-stage schizophrenia. Journal of Psychiatric Research. 45: 756-62. PMID 20937506 DOI: 10.1016/j.jpsychires.2010.09.003  0.72
2011 Souza RP, Rosa DV, Romano-Silva MA, Zhen M, Meltzer HY, Lieberman JA, Remington G, Kennedy JL, Wong AH. Lack of association of NALCN genetic variants with schizophrenia. Psychiatry Research. 185: 450-2. PMID 20674038 DOI: 10.1016/j.psychres.2010.07.009  0.72
2011 Slifstein M, Suckow RF, Javitch JA, Cooper T, Lieberman J, Abi-Dargham A. Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 31: 293-304. PMID 20571519 DOI: 10.1038/jcbfm.2010.91  0.72
2011 Rosenfeld AJ, Lieberman JA, Jarskog LF. Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. Schizophrenia Bulletin. 37: 1077-87. PMID 20308198 DOI: 10.1093/schbul/sbq015  0.72
2011 McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Molecular Psychiatry. 16: 76-85. PMID 19721433 DOI: 10.1038/mp.2009.89  0.72
2011 Lyon GJ, Abi-Dargham A, Moore H, Lieberman JA, Javitch JA, Sulzer D. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophrenia Bulletin. 37: 108-17. PMID 19525353 DOI: 10.1093/schbul/sbp010  0.72
2011 Davis SM, Stroup TS, Koch GG, Davis CE, Rosenheck RA, Lieberman JA. Time to all-cause treatment discontinuation as the primary outcome in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia study Statistics in Biopharmaceutical Research. 3: 253-265. DOI: 10.1198/sbr.2011.10013  0.72
2011 Ballon JS, Girgis RR, Lieberman JA. Personalized Medicine for Schizophrenia Integrative Neuroscience and Personalized Medicine. DOI: 10.1093/acprof:oso/9780195393804.003.0006  0.72
2011 Geddes JR, Stroup TS, Lieberman JA. Comparative Efficacy and Effectiveness in the Drug Treatment of Schizophrenia Schizophrenia: Third Edition. 525-539. DOI: 10.1002/9781444327298.ch25  0.72
2010 Rodríguez-Murillo L, Lieberman JA. [A genetic signature for complex psychiatric diseases]. Revista De Psiquiatrí́a Y Salud Mental. 3: 75-8. PMID 23445992 DOI: 10.1016/j.rpsm.2010.09.002  0.72
2010 Sicard MN, Zai CC, Tiwari AK, Souza RP, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics. 11: 1561-71. PMID 21121776 DOI: 10.2217/pgs.10.123  0.72
2010 Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR. Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. Journal of Clinical Psychopharmacology. 30: 683-7. PMID 21105282 DOI: 10.1097/JCP.0b013e3181fa05bb  0.72
2010 Souza RP, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL. Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. Human Psychopharmacology. 25: 582-5. PMID 20860064 DOI: 10.1002/hup.1146  0.72
2010 Tiwari AK, Rodgers JB, Sicard M, Zai CC, Likhodi O, Freeman N, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ. Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 1484-90. PMID 20732371 DOI: 10.1016/j.pnpbp.2010.08.009  0.72
2010 Huang J, Perlis RH, Lee PH, Rush AJ, Fava M, Sachs GS, Lieberman J, Hamilton SP, Sullivan P, Sklar P, Purcell S, Smoller JW. Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. The American Journal of Psychiatry. 167: 1254-63. PMID 20713499 DOI: 10.1176/appi.ajp.2010.09091335  0.72
2010 Smith T, Weston C, Lieberman J. Schizophrenia (maintenance treatment). American Family Physician. 82: 338-9. PMID 20704164  0.72
2010 Zai CC, Manchia M, De Luca V, Tiwari AK, Squassina A, Zai GC, Strauss J, Shaikh SA, Freeman N, Meltzer HY, Lieberman J, Le Foll B, Kennedy JL. Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case-control and family based study designs. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 1412-8. PMID 20667458 DOI: 10.1016/j.pnpbp.2010.07.019  0.72
2010 Novak G, Zai CC, Mirkhani M, Shaikh S, Vincent JB, Meltzer H, Lieberman JA, Strauss J, Lévesque D, Kennedy JL, Le Foll B. Replicated association of the NR4A3 gene with smoking behaviour in schizophrenia and in bipolar disorder. Genes, Brain, and Behavior. 9: 910-7. PMID 20659174 DOI: 10.1111/j.1601-183X.2010.00631.x  0.72
2010 Souza RP, Remington G, Chowdhury NI, Lau MK, Voineskos AN, Lieberman JA, Meltzer HY, Kennedy JL. Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20: 688-94. PMID 20605420 DOI: 10.1016/j.euroneuro.2010.05.002  0.72
2010 Zai CC, Tiwari AK, Müller DJ, De Luca V, Shinkai T, Shaikh S, Ni X, Sibony D, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. The catechol-O-methyl-transferase gene in tardive dyskinesia. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 11: 803-12. PMID 20586531 DOI: 10.3109/15622975.2010.486043  0.72
2010 Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE, Markx S, Lieberman JA, Javitch JA. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends in Pharmacological Sciences. 31: 381-90. PMID 20579747 DOI: 10.1016/j.tips.2010.05.004  0.72
2010 Gilmore JH, Kang C, Evans DD, Wolfe HM, Smith JK, Lieberman JA, Lin W, Hamer RM, Styner M, Gerig G. Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia. The American Journal of Psychiatry. 167: 1083-91. PMID 20516153 DOI: 10.1176/appi.ajp.2010.09101492  0.72
2010 Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. Journal of the American Academy of Child and Adolescent Psychiatry. 49: 583-94; quiz 632. PMID 20494268 DOI: 10.1016/j.jaac.2010.03.013  0.72
2010 Konneker TI, Crowley JJ, Quackenbush CR, Keefe RS, Perkins DO, Stroup TS, Lieberman JA, van den Oord E, Sullivan PF. No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 1115-7. PMID 20468059 DOI: 10.1002/ajmg.b.31077  0.72
2010 Souza RP, Remington G, Meltzer HY, Lieberman JA, Kennedy JL, Wong AH. Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia. International Clinical Psychopharmacology. 25: 264-9. PMID 20436352 DOI: 10.1097/YIC.0b013e32833a5ff9  0.72
2010 Tiwari AK, Zai CC, Meltzer HY, Lieberman JA, Müller DJ, Kennedy JL. Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. Human Psychopharmacology. 25: 253-9. PMID 20373477 DOI: 10.1002/hup.1111  0.72
2010 Souza RP, de Luca V, Remington G, Lieberman JA, Meltzer HY, Kennedy JL, Wong AH. Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. Psychopharmacology. 210: 347-54. PMID 20369355 DOI: 10.1007/s00213-010-1829-4  0.72
2010 Merrill DB, Girgis RR, Bickford LC, Vorel SR, Lieberman JA. Teaching trainees to negotiate research collaborations with industry: a mentorship model. The American Journal of Psychiatry. 167: 381-6. PMID 20360328 DOI: 10.1176/appi.ajp.2009.08121886  0.72
2010 Hooper SR, Giuliano AJ, Youngstrom EA, Breiger D, Sikich L, Frazier JA, Findling RL, McClellan J, Hamer RM, Vitiello B, Lieberman JA. Neurocognition in early-onset schizophrenia and schizoaffective disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 49: 52-60. PMID 20215926 DOI: 10.1097/00004583-201001000-00009  0.72
2010 Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 13: 793-8. PMID 20196918 DOI: 10.1017/S1461145710000167  0.72
2010 Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenetics and Genomics. 20: 274-6. PMID 20168265 DOI: 10.1097/FPC.0b013e328337ce3e  0.72
2010 Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, MacNeil LT, Culotti JG, Kennedy JL, Wong AH. Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. Journal of Psychiatric Research. 44: 700-6. PMID 20116071 DOI: 10.1016/j.jpsychires.2010.01.002  0.72
2010 Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP, Batra P, Zaidi SH, Chen S, Liu F, Puls I, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 1315-24. PMID 20107430 DOI: 10.1038/npp.2009.235  0.72
2010 Glantz LA, Gilmore JH, Overstreet DH, Salimi K, Lieberman JA, Jarskog LF. Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. Schizophrenia Research. 118: 292-9. PMID 20067857 DOI: 10.1016/j.schres.2009.12.027  0.72
2010 Hwang R, Zai C, Tiwari A, Müller DJ, Arranz MJ, Morris AG, McKenna PJ, Munro J, Potkin SG, Lieberman JA, Meltzer HY, Kennedy JL. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. The Pharmacogenomics Journal. 10: 200-18. PMID 20029384 DOI: 10.1038/tpj.2009.65  0.72
2010 Novak G, Gallo A, Zai CC, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN, Remington G, Kennedy JL, Levesque D, Le Foll B. Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. Psychiatric Genetics. 20: 39-43. PMID 20010315 DOI: 10.1097/YPG.0b013e3283351221  0.72
2010 Hirata Y, Souza RP, Lieberman JA, Meltzer HY, Kennedy JL. Lack of association between HTR4 gene polymorphisms and schizophrenia in case-control and family-based samples. Psychiatry Research. 175: 176-8. PMID 19892407 DOI: 10.1016/j.psychres.2009.08.005  0.72
2010 Aberg K, Adkins DE, Bukszár J, Webb BT, Caroff SN, Miller DD, Sebat J, Stroup S, Fanous AH, Vladimirov VI, McClay JL, Lieberman JA, Sullivan PF, van den Oord EJ. Genomewide association study of movement-related adverse antipsychotic effects. Biological Psychiatry. 67: 279-82. PMID 19875103 DOI: 10.1016/j.biopsych.2009.08.036  0.72
2010 Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA. Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research. 116: 118-25. PMID 19864114 DOI: 10.1016/j.schres.2009.09.026  0.72
2010 Zai CC, Tiwari AK, Basile V, de Luca V, Müller DJ, Voineskos AN, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 50-6. PMID 19778569 DOI: 10.1016/j.pnpbp.2009.09.020  0.72
2010 Kimhy D, Delespaul P, Ahn H, Cai S, Shikhman M, Lieberman JA, Malaspina D, Sloan RP. Concurrent measurement of "real-world" stress and arousal in individuals with psychosis: assessing the feasibility and validity of a novel methodology. Schizophrenia Bulletin. 36: 1131-9. PMID 19429846 DOI: 10.1093/schbul/sbp028  0.72
2010 Rosenheck RA, Scott Stroup T, Lieberman JA. Conclusion and implications for practice and policy Antipsychotic Trials in Schizophrenia: the Catie Project. 288-306. DOI: 10.1017/CBO9780511712265.018  0.72
2010 Scott Stroup TS, Lieberman JA. Implications for research design and study implementation Antipsychotic Trials in Schizophrenia: the Catie Project. 281-287. DOI: 10.1017/CBO9780511712265.017  0.72
2010 McEvoy JP, Scott Stroup T, Lieberman JA. Effectiveness and efficacy: Staying on treatment and symptom reduction Antipsychotic Trials in Schizophrenia: the Catie Project. 39-56. DOI: 10.1017/CBO9780511712265.004  0.72
2010 Scott Stroup T, McEvoy JP, Lieberman JA. Study design and protocol development process Antipsychotic Trials in Schizophrenia: the Catie Project. 1-21. DOI: 10.1017/CBO9780511712265.002  0.72
2009 Shi X, Styner M, Lieberman J, Ibrahim JG, Lin W, Zhu H. Intrinsic Regression Models for Manifold-Valued Data. Journal of the American Statistical Association. 5762: 192-199. PMID 19960103 DOI: 10.1007/978-3-642-04271-3_24  0.72
2009 Souza RP, Tampakeras M, Basile V, Shinkai T, Rosa DV, Potkin S, Meltzer HY, Lieberman JA, Romano-Silva MA, Kennedy JL. Lack of association of GPX1 and MnSOD genes with symptom severity and response to clozapine treatment in schizophrenia subjects. Human Psychopharmacology. 24: 676-9. PMID 19946932 DOI: 10.1002/hup.1076  0.72
2009 McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, Perkins DO, Dickel DE, Kusenda M, Krastoshevsky O, Krause V, Kumar RA, Grozeva D, Malhotra D, Walsh T, ... ... Lieberman JA, et al. Microduplications of 16p11.2 are associated with schizophrenia. Nature Genetics. 41: 1223-7. PMID 19855392 DOI: 10.1038/ng.474  0.72
2009 Penn DL, Keefe RS, Davis SM, Meyer PS, Perkins DO, Losardo D, Lieberman JA. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research. 115: 17-23. PMID 19766459 DOI: 10.1016/j.schres.2009.08.016  0.48
2009 Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode schizophrenia: a comparative review. Cns Drugs. 23: 837-55. PMID 19739694 DOI: 10.2165/11314280-000000000-00000  0.72
2009 Zai CC, Tiwari AK, King N, De Luca V, Mueller DJ, Shaikh S, Wong GW, Meltzer HY, Lieberman JA, Kennedy JL. Association study of the gamma-aminobutyric acid type a receptor gamma2 subunit gene with schizophrenia. Schizophrenia Research. 114: 33-8. PMID 19682861 DOI: 10.1016/j.schres.2009.07.010  0.72
2009 Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao JK, Swartz MS, Stroup TS, Lieberman JA. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry. 66: 1013-22. PMID 19640511 DOI: 10.1016/j.biopsych.2009.06.005  0.72
2009 Sickert L, Müller DJ, Tiwari AK, Shaikh S, Zai C, De Souza R, De Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics. 10: 1169-76. PMID 19604092 DOI: 10.2217/pgs.09.43  0.72
2009 Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, Strauss JL, Naylor JC, Payne VM, Lieberman JA, Savitz AJ, Leimone LA, Dunn L, Porcu P, Morrow AL, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 1885-903. PMID 19339966 DOI: 10.1038/npp.2009.26  0.72
2009 Reaven GM, Lieberman JA, Sethuraman G, Kraemer H, Davis JM, Blasey C, Tsuang MT, Schatzberg AF. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. Journal of Psychiatric Research. 43: 997-1002. PMID 19268968 DOI: 10.1016/j.jpsychires.2009.01.010  0.72
2009 Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, Andreasen NC, Brady KT, Brent DA, Brzustowicz L, Carter CS, Eisenberg L, Goldman H, Javitt DC, Leibenluft E, ... Lieberman JA, et al. Conflict of interest-- an issue for every psychiatrist. The American Journal of Psychiatry. 166: 274. PMID 19255048 DOI: 10.1176/appi.ajp.2009.09010093  0.72
2009 Zai CC, Tiwari AK, Basile V, De Luca V, Müller DJ, King N, Voineskos AN, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. The Pharmacogenomics Journal. 9: 168-74. PMID 19238168 DOI: 10.1038/tpj.2009.2  0.72
2009 Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia Neuropsychopharmacology. 34: 1322-1329. PMID 19005465 DOI: 10.1038/npp.2008.200  0.72
2009 Thompson PM, Bartzokis G, Hayashi KM, Klunder AD, Lu PH, Edwards N, Hong MS, Yu M, Geaga JA, Toga AW, Charles C, Perkins DO, McEvoy J, Hamer RM, Tohen M, ... ... Lieberman JA, et al. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cerebral Cortex (New York, N.Y. : 1991). 19: 1107-23. PMID 18842668 DOI: 10.1093/cercor/bhn152  0.72
2008 Morey RA, Mitchell TV, Inan S, Lieberman JA, Belger A. Neural correlates of automatic and controlled auditory processing in schizophrenia. The Journal of Neuropsychiatry and Clinical Neurosciences. 20: 419-30. PMID 19196926 DOI: 10.1176/appi.neuropsych.20.4.419  0.72
2008 Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacological Reviews. 60: 358-403. PMID 18922967 DOI: 10.1124/pr.107.00107  0.72
2008 Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research. 105: 175-87. PMID 18775645 DOI: 10.1016/j.schres.2008.07.006  0.72
2008 Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, Lieberman JA. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 193: 37-43. PMID 18700216 DOI: 10.1192/bjp.bp.107.042630  0.72
2008 Lieberman JA, Javitch JA, Moore H. Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. The American Journal of Psychiatry. 165: 931-6. PMID 18676593 DOI: 10.1176/appi.ajp.2008.08050769  0.72
2008 Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, Adams DH, Lindenmayer JP, McEvoy JP, Buckley PF, Lieberman JA, Meltzer HY, Wilson DR, Citrome L. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. Journal of Clinical Psychopharmacology. 28: 392-400. PMID 18626265 DOI: 10.1097/JCP.0b013e31817e63a5  0.72
2008 Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophrenia Research. 103: 104-9. PMID 18534821 DOI: 10.1016/j.schres.2008.04.023  0.72
2008 Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. The American Journal of Psychiatry. 165: 844-54. PMID 18519523 DOI: 10.1176/appi.ajp.2008.07111779  0.72
2008 Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, Wong AH, Kennedy JL. Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology. 200: 177-86. PMID 18500637 DOI: 10.1007/s00213-008-1193-9  0.72
2008 Naylor JC, Hulette CM, Steffens DC, Shampine LJ, Ervin JF, Payne VM, Massing MW, Kilts JD, Strauss JL, Calhoun PS, Calnaido RP, Blazer DG, Lieberman JA, Madison RD, Marx CE. Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer's disease, and related to neuropathological disease stage. The Journal of Clinical Endocrinology and Metabolism. 93: 3173-8. PMID 18477662 DOI: 10.1210/jc.2007-1229  0.72
2008 Lieberman JA, Drake RE, Sederer LI, Belger A, Keefe R, Perkins D, Stroup S. Science and recovery in schizophrenia. Psychiatric Services (Washington, D.C.). 59: 487-96. PMID 18451003 DOI: 10.1176/appi.ps.59.5.487  0.72
2008 Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Molecular Psychiatry. 13: 918-29. PMID 18414407 DOI: 10.1038/mp.2008.40  0.72
2008 Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. The Journal of Clinical Psychiatry. 69: 106-13. PMID 18312044 DOI: 10.4088/JCP.V69N0114  0.72
2008 Crowley JJ, Keefe RS, Perkins DO, Stroup TS, Lieberman JA, Sullivan PF. The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 147: 1298-300. PMID 18286587 DOI: 10.1002/ajmg.b.30727  0.72
2008 Hill SK, Sweeney JA, Hamer RM, Keefe RS, Perkins DO, Gu H, McEvoy JP, Lieberman JA. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. Journal of the International Neuropsychological Society : Jins. 14: 209-21. PMID 18282319 DOI: 10.1017/S1355617708080570  0.72
2008 Campbell DB, Lange LA, Skelly T, Lieberman J, Levitt P, Sullivan PF. Association of RGS2 and RGS5 variants with schizophrenia symptom severity. Schizophrenia Research. 101: 67-75. PMID 18262772 DOI: 10.1016/j.schres.2008.01.006  0.72
2008 Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophrenia Research. 101: 273-86. PMID 18258416 DOI: 10.1016/j.schres.2007.12.487  0.72
2008 Girgis RR, Schobel SA, Lieberman JA. Biological treatments for psychotic disorders Essential Psychiatry, Fourth Edition. 586-621. DOI: 10.1017/CBO9780511544125.027  0.72
2008 Tasman A, Kay J, Lieberman JA. Preface to the Second Edition Psychiatry: Third Edition. 1: xliii. DOI: 10.1002/9780470515167  0.72
2007 Renou J, De Luca V, Zai CC, Bulgin N, Remington G, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL. Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia. Molecular Psychiatry. 12: 1058-60. PMID 18043709 DOI: 10.1038/sj.mp.4002092  0.72
2007 Gilmore JH, Lin W, Corouge I, Vetsa YS, Smith JK, Kang C, Gu H, Hamer RM, Lieberman JA, Gerig G. Early postnatal development of corpus callosum and corticospinal white matter assessed with quantitative tractography. Ajnr. American Journal of Neuroradiology. 28: 1789-95. PMID 17923457 DOI: 10.3174/ajnr.A0651  0.72
2007 Glantz LA, Gilmore JH, Hamer RM, Lieberman JA, Jarskog LF. Synaptophysin and postsynaptic density protein 95 in the human prefrontal cortex from mid-gestation into early adulthood Neuroscience. 149: 582-591. PMID 17916412 DOI: 10.1016/j.neuroscience.2007.06.036  0.72
2007 De Luca V, Müller DJ, Hwang R, Lieberman JA, Volavka J, Meltzer HY, Kennedy JL. HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. Human Psychopharmacology. 22: 463-7. PMID 17702092 DOI: 10.1002/hup.868  0.72
2007 Frazier JA, McClellan J, Findling RL, Vitiello B, Anderson R, Zablotsky B, Williams E, McNamara NK, Jackson JA, Ritz L, Hlastala SA, Pierson L, Varley JA, Puglia M, Maloney AE, ... ... Lieberman JA, et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. Journal of the American Academy of Child and Adolescent Psychiatry. 46: 979-88. PMID 17667477 DOI: 10.1097/chi.0b013e31807083fd  0.72
2007 McClellan J, Sikich L, Findling RL, Frazier JA, Vitiello B, Hlastala SA, Williams E, Ambler D, Hunt-Harrison T, Maloney AE, Ritz L, Anderson R, Hamer RM, Lieberman JA. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. Journal of the American Academy of Child and Adolescent Psychiatry. 46: 969-78. PMID 17667476 DOI: 10.1097/CHI.0b013e3180691779  0.72
2007 Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophrenia Bulletin. 33: 1120-30. PMID 17641146 DOI: 10.1093/schbul/sbm083  0.72
2007 Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. The American Journal of Psychiatry. 164: 1061-71. PMID 17606658 DOI: 10.1176/AJP.2007.164.7.1061  0.72
2007 McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. The American Journal of Psychiatry. 164: 1050-60. PMID 17606657 DOI: 10.1176/ajp.2007.164.7.1050  0.72
2007 Steen RG, Hamer RM, Lieberman JA. Measuring brain volume by MR imaging: Impact of measurement precision and natural variation on sample size requirements American Journal of Neuroradiology. 28: 1119-1125. PMID 17569971 DOI: 10.3174/ajnr.A0537  0.72
2007 Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, ... ... Lieberman JA, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry. 64: 633-47. PMID 17548746 DOI: 10.1001/archpsyc.64.6.633  0.72
2007 Newcomer JW, Lieberman JA. Comparing safety and tolerability of antipsychotic treatment The Journal of Clinical Psychiatry. 68. PMID 17388701 DOI: 10.4088/JCP.0307E07  0.72
2007 Rosenheck RA, Lieberman JA. Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia The Journal of Clinical Psychiatry. 68. PMID 17335313 DOI: 10.4088/JCP.0207E05  0.72
2007 Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials The Journal of Clinical Psychiatry. 68. PMID 17335312 DOI: 10.4088/JCP.0207E04  0.72
2007 Lieberman JA, Perkins DO, Jarskog LF. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. Cns Spectrums. 12: 1-13; quiz 14. PMID 17329984 DOI: 10.1017/S1092852900025906  0.72
2007 Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American Journal of Psychiatry. 164: 428-36. PMID 17329467 DOI: 10.1176/AJP.2007.164.3.428  0.72
2007 Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. The American Journal of Psychiatry. 164: 415-27. PMID 17329466 DOI: 10.1176/AJP.2007.164.3.415  0.72
2007 Gilmore JH, Lin W, Prastawa MW, Looney CB, Vetsa YS, Knickmeyer RC, Evans DD, Smith JK, Hamer RM, Lieberman JA, Gerig G. Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 1255-60. PMID 17287499 DOI: 10.1523/JNEUROSCI.3339-06.2007  0.72
2007 Lieberman JA, Harvey PD, Newcomer JW, Rosenheck RA. Practical applications of recent antipsychotic effectiveness data Journal of Clinical Psychiatry. 68: 151-162. PMID 17284143 DOI: 10.4088/JCP.V68N0120  0.72
2007 Hwang R, Shinkai T, De Luca V, Ni X, Potkin SG, Lieberman JA, Meltzer HY, Kennedy JL. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. Journal of Psychopharmacology (Oxford, England). 21: 718-27. PMID 17092969 DOI: 10.1177/0269881106072341  0.72
2007 Zai CC, Hwang RW, De Luca V, Müller DJ, King N, Zai GC, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 10: 639-51. PMID 16959057 DOI: 10.1017/S1461145706007152  0.72
2007 Jarskog LF, Gilmore JH, Glantz LA, Gable KL, German TT, Tong RI, Lieberman JA. Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 95-102. PMID 16641945 DOI: 10.1038/sj.npp.1301074  0.72
2007 Stroup TS, McEvoy JP, Swartz MS, Hamer RM, Perkins DO, Lieberman JA. Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH schizophrenia trials network study Clinical Schizophrenia and Related Psychoses. 1: 69-72. DOI: 10.3371/CSRP.1.1.6  0.72
2007 Keefe RSE, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Dr. Keefe and colleagues reply American Journal of Psychiatry. 164: 1911-1912. DOI: 10.1176/appi.ajp.2007.07071086r  0.72
2007 Stroup TS, Rosenheck RA, Essock SE, Lieberman JA. Drs. Stroup, Rosenheck, Essock, and Lieberman Reply [2] American Journal of Psychiatry. 164: 1266-1267. DOI: 10.1176/appi.ajp.2007.07030404r  0.72
2006 Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American Journal of Psychiatry. 163: 2080-9. PMID 17151158 DOI: 10.1176/appi.ajp.163.12.2080  0.72
2006 Hoptman MJ, Volavka J, Czobor P, Gerig G, Chakos M, Blocher J, Citrome LL, Sheitman B, Lindenmayer JP, Lieberman JA, Bilder RM. Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder. The Journal of Neuropsychiatry and Clinical Neurosciences. 18: 509-15. PMID 17135376 DOI: 10.1176/appi.neuropsych.18.4.509  0.72
2006 Duncan GE, Moy SS, Lieberman JA, Koller BH. Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacology, Biochemistry, and Behavior. 85: 481-91. PMID 17097724 DOI: 10.1016/j.pbb.2006.09.017  0.72
2006 van der Stelt O, Lieberman JA, Belger A. Attentional modulation of early-stage visual processing in schizophrenia. Brain Research. 1125: 194-8. PMID 17087921 DOI: 10.1016/j.brainres.2006.09.099  0.72
2006 Jarskog LF, Lieberman JA. Neuroprotection in schizophrenia Journal of Clinical Psychiatry. 67. PMID 17081076 DOI: 10.4088/JCP.0906e09  0.72
2006 Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. The New England Journal of Medicine. 355: 1525-38. PMID 17035647 DOI: 10.1056/NEJMoa061240  0.72
2006 Lieberman JA. Comparative effectiveness of antipsychotic drugs: A commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Archives of General Psychiatry. 63: 1069-1072. PMID 17015808 DOI: 10.1001/archpsyc.63.10.1069  0.72
2006 Marx CE, Trost WT, Shampine LJ, Stevens RD, Hulette CM, Steffens DC, Ervin JF, Butterfield MI, Blazer DG, Massing MW, Lieberman JA. The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biological Psychiatry. 60: 1287-94. PMID 16997284 DOI: 10.1016/j.biopsych.2006.06.017  0.72
2006 Maynard TM, Meechan DW, Heindel CC, Peters AZ, Hamer RM, Lieberman JA, LaMantia AS. No evidence for parental imprinting of mouse 22q11 gene orthologs. Mammalian Genome : Official Journal of the International Mammalian Genome Society. 17: 822-32. PMID 16897343 DOI: 10.1007/s00335-006-0011-0  0.72
2006 Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophrenia Research. 86: 234-43. PMID 16887334 DOI: 10.1016/j.schres.2006.06.021  0.72
2006 Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Cañive JM, Lieberman JA. Components and correlates of family burden in schizophrenia Psychiatric Services. 57: 1117-1125. PMID 16870962 DOI: 10.1176/ps.2006.57.8.1117  0.72
2006 Lieberman JA. What the CATIE study means for clinical practice Psychiatric Services. 57: 1075. PMID 16870955 DOI: 10.1176/appi.ps.57.8.1075  0.72
2006 Lieberman JA, Jarskog LF, Malaspina D. Preventing clinical deterioration in the course of schizophrenia: The potential for neuroprotection Journal of Clinical Psychiatry. 67: 983-990. PMID 16848659 DOI: 10.4088/JCP.V67N0616  0.72
2006 Venkatraman TN, Hamer RM, Perkins DO, Song AW, Lieberman JA, Steen RG. Single-voxel 1H PRESS at 4.0 T: precision and variability of measurements in anterior cingulate and hippocampus. Nmr in Biomedicine. 19: 484-91. PMID 16763968 DOI: 10.1002/nbm.1055  0.48
2006 Swanson JW, Swartz MS, Van Dorn RA, Elbogen EB, Wagner HR, Rosenheck RA, Stroup TS, McEvoy JP, Lieberman JA. A national study of violent behavior in persons with schizophrenia. Archives of General Psychiatry. 63: 490-9. PMID 16651506 DOI: 10.1001/archpsyc.63.5.490  0.72
2006 Gizerian SS, Moy SS, Lieberman JA, Grobin AC. Neonatal neurosteroid administration results in development-specific alterations in prepulse inhibition and locomotor activity: neurosteroids alter prepulse inhibition and locomotor activity. Psychopharmacology. 186: 334-42. PMID 16586090 DOI: 10.1007/s00213-006-0360-0  0.72
2006 Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. The American Journal of Psychiatry. 163: 611-22. PMID 16585435 DOI: 10.1176/appi.ajp.163.4.611  0.72
2006 McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry. 163: 600-10. PMID 16585434 DOI: 10.1176/appi.ajp.163.4.600  0.72
2006 Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Research. 83: 53-63. PMID 16529910 DOI: 10.1016/j.schres.2005.10.016  0.72
2006 Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, Altamura AC, Andreasen N, Barnes TRE, Beckmann H, Ciprian-Ollivier J, Crow T, David A, Davidson M, Deakin B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Long-term treatment of schizophrenia World Journal of Biological Psychiatry. 7: 5-40. PMID 16509050 DOI: 10.1080/15622970500483177  0.72
2006 Umbricht DS, Bates JA, Lieberman JA, Kane JM, Javitt DC. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biological Psychiatry. 59: 762-72. PMID 16497277 DOI: 10.1016/j.biopsych.2005.08.030  0.72
2006 Bilder RM, Reiter G, Bates J, Lencz T, Szeszko P, Goldman RS, Robinson D, Lieberman JA, Kane JM. Cognitive development in schizophrenia: follow-back from the first episode. Journal of Clinical and Experimental Neuropsychology. 28: 270-82. PMID 16484098 DOI: 10.1080/13803390500360554  0.72
2006 Grobin AC, Gizerian S, Lieberman JA, Morrow AL. Perinatal allopregnanolone influences prefrontal cortex structure, connectivity and behavior in adult rats. Neuroscience. 138: 809-19. PMID 16457952 DOI: 10.1016/j.neuroscience.2005.12.026  0.72
2006 Lieberman JA, Hsiao JK. Interpreting the results of the CATIE study [1] Psychiatric Services. 57: 139. PMID 16399980 DOI: 10.1176/appi.ps.57.1.139  0.72
2006 Marx CE, Stevens RD, Shampine LJ, Uzunova V, Trost WT, Butterfield MI, Massing MW, Hamer RM, Morrow AL, Lieberman JA. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 1249-63. PMID 16319920 DOI: 10.1038/sj.npp.1300952  0.72
2006 Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophrenia Research. 81: 47-63. PMID 16226876 DOI: 10.1016/j.schres.2005.08.014  0.72
2006 Lieberman JA, Tasman A. Handbook of Psychiatric Drugs Handbook of Psychiatric Drugs. 1-264. DOI: 10.1002/0470029439  0.72
2005 Kraus JE, Sheitman BB, Cook A, Reviere R, Lieberman JA. Olanzapine versus risperidone in newly admitted acutely ill psychotic patients Journal of Clinical Psychiatry. 66: 1564-1568. PMID 16401158 DOI: 10.4088/JCP.V66N1211  0.72
2005 Nemeroff CB, Lieberman JA, Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, Kilts CD, Daniel DG. From clinical research to clinical practice: a 4-year review of ziprasidone. Cns Spectrums. 10: 1-20. PMID 16381088 DOI: 10.1017/S1092852900019842  0.72
2005 Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. The American Journal of Psychiatry. 162: 2220-32. PMID 16330584 DOI: 10.1176/appi.ajp.162.12.2220  0.72
2005 Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. The British Journal of Psychiatry : the Journal of Mental Science. 187: 537-43. PMID 16319406 DOI: 10.1192/bjp.187.6.537  0.48
2005 Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. The American Journal of Psychiatry. 162: 1785-804. PMID 16199825 DOI: 10.1176/appi.ajp.162.10.1785  0.72
2005 Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research. 80: 45-53. PMID 16198088 DOI: 10.1016/j.schres.2005.08.010  0.72
2005 Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine. 353: 1209-23. PMID 16172203 DOI: 10.1056/NEJMoa051688  0.72
2005 Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. The American Journal of Psychiatry. 162: 1744-6. PMID 16135638 DOI: 10.1176/appi.ajp.162.9.1744  0.72
2005 Pinkham A, Penn D, Wangelin B, Perkins D, Gerig G, Gu H, Lieberman J. Facial emotion perception and fusiform gyrus volume in first episode schizophrenia. Schizophrenia Research. 79: 341-3. PMID 16125902 DOI: 10.1016/j.schres.2005.07.012  0.72
2005 Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: A systematic review and meta-analysis Neuropsychopharmacology. 30: 1949-1962. PMID 16123764 DOI: 10.1038/sj.npp.1300850  0.72
2005 Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, Lieberman JA, Glick I, Patel JK. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophrenia Research. 78: 161-9. PMID 15950436 DOI: 10.1016/j.schres.2005.04.017  0.72
2005 van der Stelt O, Lieberman JA, Belger A. Auditory P300 in high-risk, recent-onset and chronic schizophrenia. Schizophrenia Research. 77: 309-20. PMID 15944141 DOI: 10.1016/j.schres.2005.04.024  0.72
2005 Volavka J, Nolan KA, Kline L, Czobor P, Citrome L, Sheitman B, Lindenmayer JP, McEvoy J, Lieberman JA. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. Schizophrenia Research. 76: 127-9. PMID 15927808 DOI: 10.1016/j.schres.2004.11.007  0.72
2005 Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA. Apoptotic mechanisms in the pathophysiology of schizophrenia Progress in Neuro-Psychopharmacology and Biological Psychiatry. 29: 846-858. PMID 15908096 DOI: 10.1016/j.pnpbp.2005.03.010  0.72
2005 Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry. 62: 361-70. PMID 15809403 DOI: 10.1001/archpsyc.62.4.361  0.72
2005 Morey RA, Inan S, Mitchell TV, Perkins DO, Lieberman JA, Belger A. Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Archives of General Psychiatry. 62: 254-62. PMID 15753238 DOI: 10.1001/archpsyc.62.3.254  0.72
2005 Graham KA, Perkins DO, Edwards LJ, Barrier RC, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. The American Journal of Psychiatry. 162: 118-23. PMID 15625209 DOI: 10.1176/appi.ajp.162.1.118  0.48
2005 Nolan KA, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome LL, McEvoy J, Lieberman JA. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. Journal of Psychiatric Research. 39: 109-15. PMID 15504429 DOI: 10.1016/j.jpsychires.2004.04.010  0.72
2005 Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry. 10: 79-104. PMID 15289815 DOI: 10.1038/sj.mp.4001556  0.72
2004 Stroup TS, McEvoy JP, Lieberman JA. Revised PORT recommendations Schizophrenia Bulletin. 30: 609-611. PMID 15631251 DOI: 10.1093/OXFORDJOURNALS.SCHBUL.A007106  0.72
2004 van der Stelt O, Belger A, Lieberman JA. Macroscopic fast neuronal oscillations and synchrony in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 101: 17567-8. PMID 15601768 DOI: 10.1073/pnas.0407688101  0.72
2004 Miyamoto S, Snouwaert JN, Koller BH, Moy SS, Lieberman JA, Duncan GE. Amphetamine-induced Fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunction. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 29: 2180-8. PMID 15467708 DOI: 10.1038/sj.npp.1300548  0.72
2004 Styner M, Lieberman JA, Pantazis D, Gerig G. Boundary and medial shape analysis of the hippocampus in schizophrenia. Medical Image Analysis. 8: 197-203. PMID 15450215 DOI: 10.1016/j.media.2004.06.004  0.72
2004 Perkins DO, Lieberman JA, Gu H, Tohen M, McEvoy J, Green AI, Zipursky RB, Strakowski SM, Sharma T, Kahn RS, Gur R, Tollefson G. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders British Journal of Psychiatry. 185: 18-24. PMID 15231551 DOI: 10.1192/bjp.185.1.18  0.48
2004 Gizerian SS, Morrow AL, Lieberman JA, Grobin AC. Neonatal neurosteroid administration alters parvalbumin expression and neuron number in medial dorsal thalamus of adult rats. Brain Research. 1012: 66-74. PMID 15158162 DOI: 10.1016/j.brainres.2004.03.049  0.72
2004 Grobin AC, Lieberman JA, Morrow AL. Perinatal flunitrazepam exposure causes persistent alteration of parvalbumin-immunoreactive interneuron localization in rat prefrontal cortex. Neuroscience Letters. 359: 9-12. PMID 15050699 DOI: 10.1016/j.neulet.2003.12.124  0.72
2004 Lieberman JA. Dopamine partial agonists: A new class of antipsychotic Cns Drugs. 18: 251-267. PMID 15015905 DOI: 10.2165/00023210-200418040-00005  0.72
2004 Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, McIntyre JS, Charles SC, Altshuler K, Cook I, Cross CD, Mellman L, Moench LA, Norquist G, et al. Practice Guideline for the Treatment of Partients with Schizophrenia, Second Edition American Journal of Psychiatry. 161: i-iv+1-56. PMID 15000267  0.48
2004 van der Stelt O, Frye J, Lieberman JA, Belger A. Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia. Archives of General Psychiatry. 61: 237-48. PMID 14993111 DOI: 10.1001/archpsyc.61.3.237  0.72
2003 Miyamoto S, LaMantia AS, Duncan GE, Sullivan P, Gilmore JH, Lieberman JA. Recent advances in the neurobiology of schizophrenia. Molecular Interventions. 3: 27-39. PMID 14993436 DOI: 10.1124/mi.3.1.27  0.72
2003 Maynard TM, Haskell GT, Peters AZ, Sikich L, Lieberman JA, LaMantia AS. A comprehensive analysis of 22q11 gene expression in the developing and adult brain. Proceedings of the National Academy of Sciences of the United States of America. 100: 14433-8. PMID 14614146 DOI: 10.1073/pnas.2235651100  0.72
2003 Bradford DW, Perkins DO, Lieberman JA. Pharmacological Management of First-Episode Schizophrenia and Related Nonaffective Psychoses Drugs. 63: 2265-2283. PMID 14524730 DOI: 10.2165/00003495-200363210-00001  0.48
2003 Szeszko PR, Gunning-Dixon F, Goldman RS, Bates J, Ashtari M, Snyder PJ, Lieberman JA, Bilder RM. Lack of normal association between cerebellar volume and neuropsychological functions in first-episode schizophrenia. The American Journal of Psychiatry. 160: 1884-7. PMID 14514506 DOI: 10.1176/appi.ajp.160.10.1884  0.72
2003 Lieberman JA, Stroup TS. Schizophrenia, VI: Treatments The American Journal of Psychiatry. 160: 1748. PMID 14514482 DOI: 10.1176/APPI.AJP.160.10.1748  0.72
2003 Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin. 29: 15-31. PMID 12908658 DOI: 10.1093/OXFORDJOURNALS.SCHBUL.A006986  0.72
2003 Lieberman JA, Stroup TS. Guest editors' introduction: What can large pragmatic clinical trials do for public mental health care? Schizophrenia Bulletin. 29: 1-6. PMID 12908656 DOI: 10.1093/OXFORDJOURNALS.SCHBUL.A006979  0.72
2003 Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. The American Journal of Psychiatry. 160: 1396-404. PMID 12900300 DOI: 10.1176/appi.ajp.160.8.1396  0.72
2003 Pinkham AE, Penn DL, Perkins DO, Lieberman J. Implications for the neural basis of social cognition for the study of schizophrenia. The American Journal of Psychiatry. 160: 815-24. PMID 12727681 DOI: 10.1176/appi.ajp.160.5.815  0.72
2003 Grobin AC, Heenan EJ, Lieberman JA, Morrow AL. Perinatal neurosteroid levels influence GABAergic interneuron localization in adult rat prefrontal cortex. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 1832-9. PMID 12629187  0.72
2003 Duncan GE, Miyamoto S, Lieberman JA. Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation. The Journal of Pharmacology and Experimental Therapeutics. 305: 999-1005. PMID 12626664 DOI: 10.1124/jpet.102.048140  0.72
2003 Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 1-13. PMID 12496935 DOI: 10.1038/sj.npp.1300015  0.72
2003 Gerig G, Muller KE, Kistner EO, Chi YY, Chakos M, Styner M, Lieberman JA. Age and treatment related local hippocampal changes in schizophrenia explained by a novel shape analysis method Lecture Notes in Computer Science. 2879: 653-660.  0.72
2002 Johns JM, Lubin DA, Lieberman JA, Lauder JM. Developmental effects of prenatal cocaine exposure on 5-HT1A receptors in male and female rat offspring. Developmental Neuroscience. 24: 522-30. PMID 12697990 DOI: 10.1159/000069363  0.72
2002 Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X, Goldman RS, Hoptman MJ, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Kunz M, Chakos M, Cooper TB, ... Lieberman JA, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biological Psychiatry. 52: 701-7. PMID 12372660 DOI: 10.1016/S0006-3223(02)01416-6  0.72
2002 Duncan G, Miyamoto S, Gu H, Lieberman J, Koller B, Snouwaert J. Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function. Brain Research. 951: 166-76. PMID 12270494 DOI: 10.1016/S0006-8993(02)03156-6  0.72
2002 Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research. 57: 209-19. PMID 12223252 DOI: 10.1016/S0920-9964(01)00312-7  0.72
2002 Spivak B, Alamy SS, Jarskog LF, Sheitman BB, Lieberman JA. Ziprasidone alternative for olanzapine-induced hyperglycemia [1] American Journal of Psychiatry. 159: 1606. PMID 12202289 DOI: 10.1176/appi.ajp.159.9.1606  0.72
2002 Maynard TM, Haskell GT, Lieberman JA, LaMantia AS. 22q11 DS: genomic mechanisms and gene function in DiGeorge/velocardiofacial syndrome. International Journal of Developmental Neuroscience : the Official Journal of the International Society For Developmental Neuroscience. 20: 407-19. PMID 12175881 DOI: 10.1016/S0736-5748(02)00050-3  0.72
2002 Andersson C, Hamer RM, Lawler CP, Mailman RB, Lieberman JA. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 27: 143-51. PMID 12093588 DOI: 10.1016/S0893-133X(02)00287-7  0.72
2002 Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. The American Journal of Psychiatry. 159: 1018-28. PMID 12042192 DOI: 10.1176/appi.ajp.159.6.1018  0.72
2002 Szeszko PR, Strous RD, Goldman RS, Ashtari M, Knuth KH, Lieberman JA, Bilder RM. Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia. The American Journal of Psychiatry. 159: 217-26. PMID 11823263 DOI: 10.1176/appi.ajp.159.2.217  0.72
2002 Maynard TM, Haskell GT, Bhasin N, Lee JM, Gassman AA, Lieberman JA, LaMantia AS. RanBP1, a velocardiofacial/DiGeorge syndrome candidate gene, is expressed at sites of mesenchymal/epithelial induction. Mechanisms of Development. 111: 177-80. PMID 11804793 DOI: 10.1016/S0925-4773(01)00616-5  0.72
2002 Lieberman JA, Perkins DO. Introduction. Quetiapine: A 5-year update Journal of Clinical Psychiatry. 63: 3-4.  0.48
2001 Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry. 50: 884-97. PMID 11743943 DOI: 10.1016/S0006-3223(01)01303-8  0.72
2001 Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Rosenheck RA, Small GW, Lebowitz B, ... Lieberman JA, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 9: 346-60. PMID 11739062 DOI: 10.1097/00019442-200111000-00004  0.72
2001 Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH. Cytokine effects on cortical neuron MAP-2 immunoreactivity: Implications for schizophrenia Biological Psychiatry. 50: 743-749. PMID 11720692 DOI: 10.1016/S0006-3223(01)01209-4  0.72
2001 Maynard TM, Sikich L, Lieberman JA, LaMantia AS. Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. Schizophrenia Bulletin. 27: 457-76. PMID 11596847 DOI: 10.1093/OXFORDJOURNALS.SCHBUL.A006887  0.72
2001 Basile VS, Ozdemir V, Masellis M, Meltzer HY, Lieberman JA, Potkin SG, Macciardi FM, Petronis A, Kennedy JL. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Molecular Psychiatry. 6: 230-4. PMID 11317228 DOI: 10.1038/sj.mp.4000847  0.72
2001 Miyamoto S, Mailman RB, Lieberman JA, Duncan GE. Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors. Brain Research. 894: 167-80. PMID 11251190 DOI: 10.1016/S0006-8993(01)01991-6  0.72
2001 Masellis M, Basile VS, Meltzer HY, Lieberman JA, Sevy S, Goldman DA, Hamblin MW, Macciardi FM, Kennedy JL. Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophrenia Research. 47: 49-58. PMID 11163544 DOI: 10.1016/S0920-9964(00)00016-5  0.72
2001 Lieberman JA. Starting a career in psychiatric research: The lessons of experience Academic Psychiatry. 25: 28-30. DOI: 10.1176/appi.ap.25.1.28  0.72
2000 Javitt DC, Shelley AM, Silipo G, Lieberman JA. Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Archives of General Psychiatry. 57: 1131-7. PMID 11115326 DOI: 10.1001/ARCHPSYC.57.12.1131  0.72
2000 Lieberman JA, Golden R, Stroup S, McEvoy J. Drugs of the psychopharmacological revolution in clinical psychiatry. Psychiatric Services (Washington, D.C.). 51: 1254-8. PMID 11013323 DOI: 10.1176/appi.ps.51.10.1254  0.72
2000 Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA. Characterizing and dating the onset of symptoms in psychotic illness: The Symptom Onset in Schizophrenia (SOS) inventory Schizophrenia Research. 44: 1-10. PMID 10867307 DOI: 10.1016/S0920-9964(99)00161-9  0.48
2000 Szeszko PR, Bilder RM, Lencz T, Ashtari M, Goldman RS, Reiter G, Wu H, Lieberman JA. Reduced anterior cingulate gyrus volume correlates with executive dysfunction in men with first-episode schizophrenia. Schizophrenia Research. 43: 97-108. PMID 10858628 DOI: 10.1016/S0920-9964(99)00155-3  0.72
2000 Marx CE, Duncan GE, Gilmore JH, Lieberman JA, Morrow AL. Olanzapine increases allopregnanolone in the rat cerebral cortex. Biological Psychiatry. 47: 1000-4. PMID 10838068 DOI: 10.1016/S0006-3223(99)00305-4  0.72
2000 Jarskog LF, Mattioli MA, Perkins DO, Lieberman JA. First-episode psychosis in a managed care setting: Clinical management and research American Journal of Psychiatry. 157: 878. PMID 10831465 DOI: 10.1176/appi.ajp.157.6.878  0.48
2000 Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, Pappadopulos E, Willson DF, Alvir JM, Woerner MG, Geisler S, Kane JM, Lieberman JA. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. The American Journal of Psychiatry. 157: 549-59. PMID 10739413 DOI: 10.1176/appi.ajp.157.4.549  0.72
2000 Vincent JB, Neves-Pereira ML, Paterson AD, Yamamoto E, Parikh SV, Macciardi F, Gurling HM, Potkin SG, Pato CN, Macedo A, Kovacs M, Davies M, Lieberman JA, Meltzer HY, Petronis A, et al. An unstable trinucleotide-repeat region on chromosome 13 implicated in spinocerebellar ataxia: a common expansion locus. American Journal of Human Genetics. 66: 819-29. PMID 10712198 DOI: 10.1086/302803  0.72
2000 Miyamoto S, Leipzig JN, Lieberman JA, Duncan GE. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 22: 400-12. PMID 10700659 DOI: 10.1016/S0893-133X(99)00127-X  0.72
2000 Lieberman JA. Clinical research in the age of neuroscience Neuropsychopharmacology. 22: 1-3. PMID 10633484 DOI: 10.1016/S0893-133X(99)00094-9  0.72
1999 Bilder RM, Wu H, Bogerts B, Ashtari M, Robinson D, Woerner M, Lieberman JA, Degreef G. Cerebral volume asymmetries in schizophrenia and mood disorders: a quantitative magnetic resonance imaging study. International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology. 34: 197-205. PMID 10610044 DOI: 10.1016/S0167-8760(99)00077-X  0.72
1999 Yui K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan GE, Sheitman BB, Lieberman JA, Bracha SH, Ali SF. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Molecular Psychiatry. 4: 512-23. PMID 10578232 DOI: 10.1038/sj.mp.4000575  0.72
1999 Hinrichsen GA, Lieberman JA. Family attributions and coping in the prediction of emotional adjustment in family members of patients with first-episode schizophrenia Acta Psychiatrica Scandinavica. 100: 359-366. PMID 10563453 DOI: 10.1111/j.1600-0447.1999.tb10879.x  0.72
1999 Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Molecular Psychiatry. 4: 418-28. PMID 10523814 DOI: 10.1038/sj.mp.4000581  0.72
1999 Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective Biological Psychiatry. 46: 729-739. PMID 10494440 DOI: 10.1016/S0006-3223(99)00147-X  0.72
1999 Lieberman JA, Aghajanian GK. Caveat emptor: researcher beware. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 21: 471-3. PMID 10481829 DOI: 10.1016/S0893-133X(99)00071-8  0.72
1999 Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis Schizophrenia Bulletin. 25: 201-222. PMID 10416727 DOI: 10.1093/OXFORDJOURNALS.SCHBUL.A033374  0.72
1999 Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA, Potkin SG, Macciardi F, Kennedy JL. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 21: 17-27. PMID 10379516 DOI: 10.1016/S0893-133X(98)00114-6  0.72
1999 Leadbetter RA, Shutty MS, Elkashef AM, Kirch DG, Spraggins T, Cail WS, Wu H, Bilder RM, Lieberman JA, Wyatt RJ. MRI changes during water loading in patients with polydipsia and intermittent hyponatremia. The American Journal of Psychiatry. 156: 958-60. PMID 10360142 DOI: 10.1176/AJP.156.6.958  0.72
1999 Lee H, Tarazi FI, Chakos M, Wu H, Redmond M, Alvir JM, Kinon BJ, Bilder R, Creese I, Lieberman JA. Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum. Life Sciences. 64: 1595-602. PMID 10328519 DOI: 10.1016/S0024-3205(99)00106-X  0.72
1999 Szeszko PR, Bilder RM, Lencz T, Pollack S, Alvir JM, Ashtari M, Wu H, Lieberman JA. Investigation of frontal lobe subregions in first-episode schizophrenia. Psychiatry Research. 90: 1-15. PMID 10320207 DOI: 10.1016/S0925-4927(99)00002-5  0.72
1999 Szeszko PR, Bilder RM, Dunlop JA, Walder DJ, Lieberman JA. Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. Biological Psychiatry. 45: 680-6. PMID 10187997 DOI: 10.1016/S0006-3223(98)00258-3  0.72
1998 Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biological Psychiatry. 44: 1099-117. PMID 9836014 DOI: 10.1016/S0006-3223(98)00187-5  0.72
1998 Sheitman BB, Lieberman JA. The natural history and pathophysiology of treatment resistant schizophrenia Journal of Psychiatric Research. 32: 143-150. PMID 9793867 DOI: 10.1016/S0022-3956(97)00052-6  0.72
1998 Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, Cola P, Howard A, Badri F, Nöthen MM, Kalow W, Kennedy JL. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 19: 123-32. PMID 9629566 DOI: 10.1016/S0893-133X(98)00007-4  0.72
1998 Perkins DO, Lieberman JA. Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs American Journal of Psychiatry. 155: 272-276. PMID 9464209  0.48
1997 Sheitman BB, Lee H, Strauss R, Lieberman JA. The evaluation and treatment of first-episode psychosis Schizophrenia Bulletin. 23: 653-661. PMID 9366001 DOI: 10.1093/SCHBUL/23.4.653  0.72
1997 Barr WB, Ashtari M, Bilder RM, Degreef G, Lieberman JA. Brain morphometric comparison of first-episode schizophrenia and temporal lobe epilepsy. The British Journal of Psychiatry : the Journal of Mental Science. 170: 515-9. PMID 9330016 DOI: 10.1192/BJP.170.6.515  0.72
1997 Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity Neuropsychopharmacology. 17: 205-229. PMID 9326746 DOI: 10.1016/S0893-133X(97)00045-6  0.72
1996 Lieberman JA, Rush AJ. Redefining the role of psychiatry in medicine American Journal of Psychiatry. 153: 1388-1397. PMID 8890670 DOI: 10.1176/AJP.153.11.1388  0.72
1996 Shelley AM, Grochowski S, Lieberman JA, Javitt DC. Premature disinhibition of P3 generation in schizophrenia. Biological Psychiatry. 39: 714-9. PMID 8731459 DOI: 10.1016/0006-3223(95)00222-7  0.72
1995 Snyder PJ, Bilder RM, Wu H, Bogerts B, Lieberman JA. Cerebellar volume asymmetries are related to handedness: a quantitative MRI study. Neuropsychologia. 33: 407-19. PMID 7617152 DOI: 10.1016/0028-3932(94)00125-9  0.72
1994 Bilder RM, Wu H, Bogerts B, Degreef G, Ashtari M, Alvir JM, Snyder PJ, Lieberman JA. Absence of regional hemispheric volume asymmetries in first-episode schizophrenia. The American Journal of Psychiatry. 151: 1437-47. PMID 8092337 DOI: 10.1176/AJP.151.10.1437  0.72
1994 Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, Wu H, Kinon B, Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. The American Journal of Psychiatry. 151: 1430-6. PMID 7916539 DOI: 10.1176/AJP.151.10.1430  0.72
1992 Bilder RM, Lipschutz-Broch L, Reiter G, Geisler SH, Mayerhoff DI, Lieberman JA. Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophrenia Bulletin. 18: 437-48. PMID 1411331 DOI: 10.1093/schbul/18.3.437  0.72
1992 Lieberman JA, Alvir JM, Woerner M, Degreef G, Bilder RM, Ashtari M, Bogerts B, Mayerhoff DI, Geisler SH, Loebel A. Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophrenia Bulletin. 18: 351-71. PMID 1411327 DOI: 10.1093/schbul/18.3.351  0.72
1991 Bilder RM, Lipschutz-Broch L, Reiter G, Geisler S, Mayerhoff D, Lieberman JA. Neuropsychological deficits in the early course of first episode schizophrenia. Schizophrenia Research. 5: 198-9. PMID 1760394 DOI: 10.1016/0920-9964(91)90071-X  0.72
1989 Kendler KS, Lieberman JA, Walsh D. The Structured Interview for Schizotypy (SIS): A preliminary report Schizophrenia Bulletin. 15: 559-571. PMID 2623438 DOI: 10.1093/SCHBUL/15.4.559  0.72
1988 Andreasen NC, Shore D, Burke JD, Grove WM, Lieberman JA, Oltmanns TF, Pettegrew JW, Pulver AE, Siever LJ, Tsuang MT. Clinical phenomenology. Schizophrenia Bulletin. 14: 345-63. PMID 2905523 DOI: 10.1093/schbul/14.3.345  0.72
Show low-probability matches.